Search Results
Your search for ,foR matches 33255 pages
Showing 23501 - 23550FDA Approves Defibrotide for Complication of Stem Cell Transplant
On March 30, 2016, the U.S. Food and Drug Administration (FDA) approved defibrotide sodium (Defitelio) for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, also known as sinusoidal obstructive syndrome, with renal or pulmonary dysfunction following hematopoietic...
Patrick Moore, MD, MPH, Named NCI Outstanding Investigator, Awarded $6.4 Million for Discovering Cancer Viruses
Patrick Moore, MD, MPH, has received the National Cancer Institute (NCI) Outstanding Investigator Award, and was awarded $6.4 million to further his work into the link between viruses and cancer. This NCI grant provides 7 years of secured support, giving the investigator freedom from the pressure...
Jennie R. Crews, MD, FACP, Named President of the Association of Community Cancer Centers
Jennie R. Crews, MD, FACP, became the new President of the Association of Community Cancer Centers (ACCC) during the recent ACCC 42nd Annual Meeting in Washington, DC. Dr. Crews brings more than 18 years of experience in advancing quality oncology care, currently as the Medical Director for Cancer ...
Providing Perspective on Pressing Economic Issues Facing Cancer Care—Now and in the Future
CANCERSCAPE, the 2016 Annual Meeting of the Association of Community Cancer Centers (ACCC), provided a forum for about 300 attendees to gain insight into the complexities of oncology treatment, where “clinical advances, policy mandates, and value-based payment reform intersect.” Of particular...
Highlights From the 2016 Quality Care Symposium and Multidisciplinary Head and Neck Cancer Symposium
Direct your patients to the Cancer.Net Blog, www.cancer.net/blog, to listen to a podcast from the 2016 Quality Care Symposium on research highlighting efforts to make sure patients are getting the most appropriate care while also addressing the costs of cancer care. Also on the blog, learn more...
ASCO Pledges to Advance Interoperability Among Health Information Systems
ASCO has joined members of the health-care community in pledging to the U.S. Department of Health and Human Services (HHS) to commit to principles that will advance interoperability among health information systems. A formal announcement of the initiative was delivered by HHS Secretary Sylvia M....
Understanding and Preparing for MACRA
The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) was passed in April 2015, introducing comprehensive changes to how Medicare pays physicians for services. As the policies passed in MACRA are rolled out over the coming years, they will profoundly impact reimbursement and care...
Donate Now to Access the Conquer Cancer Foundation Donor Lounge at ASCO Annual Meeting
The Foundation’s Donor Lounge is the perfect space to recharge or meet with friends and colleagues during ASCO’s Annual Meeting. It’s where industry leaders network and enjoy access to complimentary light refreshments and where busy attendees escape for a quiet place to relax. Make accessing this...
Diversity Training Key to Increasing Cultural Competence Among Oncology Surgeons
A study in the Journal of Oncology Practice (JOP)1 measured the level of cultural competence among surgeons from six hospitals in the Puget Sound region of Washington State, home to a large population of American Indians and Alaskan Natives. According to the study, “Assessing Cultural Competence...
Conquer Cancer Foundation Honors 74 Oncologists for Contributions to Genitourinary Cancer, Cancer Survivorship, Gastrointestinal Cancer, and Quality Care Research
The Conquer Cancer Foundation of ASCO is pleased to announce the recipients of its 2016 Conquer Cancer Foundation of ASCO Merit Awards in Gastrointestinal Cancer, Genitourinary Cancer, Cancer Survivorship, and Quality Care. The following 74 young investigators, recognized for the scientific merit...
Update of ASCEND-1 Trial Shows Ceritinib Highly Active in ALK-Rearranged NSCLC, Including Intracranial Disease
Updated results of the phase I ASCEND-1 trial, reported by Kim et al in The Lancet Oncology, indicate that the ALK inhibitor ceritinib (Zykadia) produced high response rates in advanced ALK-rearranged non–small cell lung cancer (NSCLC), including intracranial disease, in both patients with and...
MicroRNA miR-181a Reduces NFκB Signaling in Diffuse Large B-Cell Lymphomas
A recent study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine showed that a microRNA called miR-181a dampens signals from the cancer-driving NFκB protein pathway in diffuse large B-cell lymphoma (DLBCL). By reducing NFκB...
NCI Announces Blue Ribbon Panel to Help Guide Vice President Biden’s National Cancer Moonshot Initiative
On April 4, 2016, The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), announced a Blue Ribbon Panel of scientific experts, cancer leaders, and patient advocates that will inform the scientific direction and goals at NCI of Vice President Joe Biden’s National...
Vitamin D Level Associated With Melanoma Outcome Independent of C-Reactive Protein Level
In a study reported in the Journal of Clinical Oncology, Fang et al found that lower vitamin D levels were associated with poorer outcome in patients with melanoma independent of C-reactive protein (CRP) levels. Study Details The study involved data from 1,042 prospectively observed patients with ...
Pathologic Complete Response to Neoadjuvant Therapy Associated With Improved Outcomes in HER2-Positive Breast Cancer
Pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer was associated with a significantly better outcome vs non–pathologic complete response, in a patient-level meta-analysis reported by Broglio et al in JAMA Oncology. Response vs No Response The study included...
New Commission on Cancer Standards Clarifies and Emphasizes Process, Quality, Data Reporting, and More
The 2016 edition of the Commission on Cancer’s accreditation standards manual clarifies and provides additional information in many areas and raises the bar for compliance in some, including psychosocial distress screening, survivorship care, data reporting, and activities in prevention and...
Outcome Measures in Quality and Identifying High-Quality Practice
At this year’s ASCO Quality Care Symposium, Craig Earle, MD, MSc, of the Ontario Institute for Cancer Research, used Donabedian’s Triad—structure, process, and outcome—to set the stage for his presentation on the science of quality. “The theory behind Donabedian’s Triad is that structure...
Experts Consider What It Means to Improve Quality of Care in an Era of Increasing Reliance on Targeted Therapies
Precision medicine is judged according to different values across the multiple stakeholders involved in cancer care. At this year’s Quality Care Symposium, presenters from different sectors of oncology addressed a central question: How do we assess quality in the age of precision medicine?1,2 Right ...
A Business Professor and Husband Turns Breast Cancer Researcher
In more than 25 years of viewing posters at oncology meetings, I’ve met researchers from virtually all professional walks of life, but it was not until the 2016 Miami Breast Cancer Conference, that the author’s affiliation turned my head: It was a business school. “Utilizing Metastatic Tumor...
Metastatic Breast Cancer With Discordant Tumors: Small Study Reports Treatment by Primary Status May Improve Survival
In a small retrospective series, patients with metastatic breast cancer treated according to the receptor status of the primary tumor, not the metastatic one, had significantly longer median overall survival. The study was reported at the 2016 Miami Breast Cancer Conference by T. Allen Pannell, Jr, ...
Jeffrey Fowler, MD, Begins Presidency of Society of Gynecologic Oncology
Jeffrey Fowler, MD, John G. Boutselis Chair in Gynecologic Oncology and Professor and Vice-Chair of Obstetrics and Gynecology at The Ohio State University Wexner Medical Center, started his 1-year term as the 48th President of the Society of Gynecologic Oncology (SGO) at the conclusion of the...
Breast Cancer Vaccines Moving Forward at a Fast Clip
Vaccines for both secondary and primary prevention of breast cancer are showing potential in clinical trials, according to Elizabeth A. Mittendorf, MD, PhD, who is leading much of the vaccine research at the University of Texas MD Anderson Cancer Center, Houston. Vaccine platforms being explored...
Expert Point of View: Kathleen Moore, MD
Session moderator Kathleen Moore, MD, Associate Professor of Obstetrics and Gynecology at the University of Oklahoma College of Medicine, Oklahoma City, said that while the response rates are “not incredibly high,” trabectedin offers another line of therapy where there previously was none. “I think ...
Trabectedin Improves Progression-Free Survival in Uterine Leiomyosarcoma
In women with uterine leiomyosarcoma, trabectedin (Yondelis), a novel cytotoxic agent, significantly improved progression-free survival, compared with dacarbazine (4.2 vs 1.5 months, hazard ratio [HR] = 0.55, P < .001). According to the study’s authors, a lack of cumulative toxicity allows...
Clifford A. Hudis, MD, FACP, Named ASCO’s Next CEO
Clifford A. Hudis, MD, FACP, Chief of the Breast Medicine Service, Vice President for Government Relations, and Chief Advocacy Officer at Memorial Sloan Kettering Cancer Center (MSKCC), and Professor of Medicine at Weill Cornell Medical College, has been named the next Chief Executive Officer...
Computer-Assisted Decision Support in Medical Oncology: We Need It Now
Today’s medical oncologist is increasingly challenged to stay current with the latest developments in cancer treatment. I have been fortunate to speak with many oncologists over the past quarter-century on how professional life has evolved since the 1990s. These conversations have left me with a...
Louis Burt Nabors, MD, on Primary and Recurrent Gliomas: Notable Developments in Management
Louis Burt Nabors, MD, of the University of Alabama at Birmingham Comprehensive Cancer Center, discusses improvements in the 2016 NCCN Guidelines for glioma, anaplastic oligodendroglioma, and glioblastoma.
Judith Paice, PhD, RN, on Managing Cancer Pain: Strategies for Prescribing Opioids
Judith Paice, PhD, RN, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses strategies for safe opioid prescribing: making a comprehensive assessment, stratifying risk, using universal precautions, and educating practitioners on safe storage and disposal.
Throwing Out the Baby With the Bathwater: A Critical Appraisal of the USPSTF Recommendation Against Screening for Prostate Cancer
In 2012, the U.S. Preventive Services Task Force (USPSTF) issued a recommendation against routine screening for prostate cancer.1,2 The grade D recommendation was considered controversial at the time, and remains so now, because many stakeholders have weighed the same body of evidence and come to...
Jeffrey Jones, MD, MPH, on Chronic Lymphocytic Leukemia: Optimizing Treatment With New Agents
Jeffrey Jones, MD, MPH, of the Ohio State University Comprehensive Cancer Center, discusses the use of small molecule inhibitors in developing an individualized treatment plan for patients with CLL.
The POPLAR Trial: PD-L1 Blockade With Atezolizumab in Second- or Third-Line Non–Small Cell Lung Cancer
The randomized phase II POPLAR trial—reported by Fehrenbacher and colleagues and reviewed in this issue of The ASCO Post—is another key piece of information for the medical community regarding the value of immune checkpoint blockers in second/third-line treatment of patients with non–small cell...
Atezolizumab Improves Survival vs Docetaxel in Previously Treated NSCLC: Increased Benefit With Increased PD-L1 Expression
In the phase II POPLAR trial reported in The Lancet, Louis Fehrenbacher, MD, of Kaiser Permanente Medical Center, and colleagues found that the investigational anti–programmed cell death ligand 1 (PD-L1) antibody atezolizumab improved overall survival vs docetaxel in patients with non–small cell...
Rogerio Lilenbaum, MD, on Metastatic NSCLC: Managing EGFR-Mutation–Positive Disease
Rogerio Lilenbaum, MD, of Yale Cancer Center/Smilow Cancer Hospital, discusses the importance of tumor profiling for non–small cell lung cancer and strategies for treating EGFR-positive disease in the first-line setting.
William Gradishar, MD, on Breast Cancer Guideline Updates
William Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, discusses updates including preoperative HER2-directed therapy, optimal adjuvant endocrine treatment in premenopausal women, and an approach for managing ER+ metastatic disease.
Glioblastoma Multiforme With Mismatch Repair Deficiency May Be Target for Immune Checkpoint Inhibition
Glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency was characterized by hypermutation and elevated neoantigen load—characteristics associated with response to immune checkpoint inhibitors in other settings—according to a study reported in the Journal of ...
Ultrasound Screening for Breast Cancer May Be Linked to Increased Detection of Invasive Tumors but More False-Positive Results
As reported in the Journal of the National Cancer Institute by Berg et al, an analysis from the American College of Radiology Imaging Network (ACRIN) 6666 study indicates that use of ultrasound in primary screening for breast cancer resulted in increased detection of invasive cancers but more...
Effects of Chemotherapy on Pregnancy for Survivors of Childhood Cancer Treated Between 1970 and 1999
In an analysis in the Childhood Cancer Survivor Study cohort reported in The Lancet Oncology, Chow et al found that increasing doses of several alkylating agents reduced the likelihood of fathering a pregnancy among male survivors of childhood cancer, with fewer drug associations with pregnancy...
ENDO 2016: Engineered Ovary Implant Restores Fertility in Mice
Northwestern University scientists used a three-dimensional (3D) printer to create a prosthetic ovary—an implant that allowed mice that had their ovaries surgically removed to bear live young. The results were presented by Laronda et al on Saturday, April 2, at the Endocrine Society's Annual...
ENDO 2016: BPA Changes Fetal Development of the Mammary Gland, Can Raise Breast Cancer Risk
A new culture system that tests the role of chemical exposure on the developing mammary gland has found that bisphenol A (BPA) directly affects the mammary gland of mouse embryos. The study results, presented by Speroni et al Friday, April 1, at the Endocrine Society's Annual Meeting in Boston...
Anne Covey, MD, on Hepatocellular Carcinoma: Guideline Updates for Locoregional Treatment
Anne Covey, MD, of Memorial Sloan Kettering Cancer Center, discusses the role of ablation and arterial-directed therapy in the treatment of hepatocellular carcinoma.
Daniel T. Chang, MD, on Hepatocellular Carcinoma: Guideline Updates for Locoregional Treatment
Daniel T. Chang, MD, of the Stanford Cancer Institute, discusses the role of radiation therapy in the treatment of hepatocellular carcinoma.
Phase II Trial Shows Benefit of Adding Ramucirumab to Docetaxel in Previously Treated Advanced Urothelial Carcinoma
Adding the anti–vascular endothelial growth factor receptor 2 (VEGFR-2) antibody ramucirumab to docetaxel improved progression-free survival among previously treated patients with locally advanced or metastatic urothelial carcinoma, reported Petrylak et al in the Journal of Clinical Oncology. ...
Good Outcome Reported With Endocrine Therapy and Omission of Chemotherapy Based on 21-Gene Recurrence Score in Breast Cancer
Treatment with adjuvant endocrine therapy and omission of chemotherapy on the basis of a 21-gene recurrence score ≤ 11 was associated with a high 3-year disease-free survival rate in women with hormone receptor–positive, HER2-negative breast cancer, according to a trial reported in...
TP53 Gene Variant S47 May Contribute to Increased Cancer Risk in People of African Descent
For years, clinical data have shown that African Americans have a higher death rate and shorter period of survival among patients with commonly diagnosed cancers. While studies have focused on whether socioeconomic factors contribute to these statistics, researchers have been diligently trying to...
Widely Cited Prostate-Specific Antigen Screening Publications Influence Biopsy Rates and Associated Complications
While absolute rates of biopsy and postbiopsy complications have decreased following several benchmark prostate-specific antigen (PSA) screening publications, the relative risk for each patient continues to increase, according to a new study by Mayo Clinic researchers. The study is the largest to...
Nadeem Abu-Rustum, MD, on Cervical Cancer: Evolving Treatment Strategies
Nadeem Abu-Rustum, MD, of Memorial Sloan Kettering Cancer Center, discusses improvements in fertility-sparing surgery for young women, advances in lymph node assessment, and the evolving role of chemotherapy and radiation.
Lung Cancer Incidence and Mortality in Individuals With a Negative Low-Dose CT Prevalence Screen
In an analysis of the National Lung Screening Trial (NLST) cohort reported in The Lancet Oncology, Patz et al found that participants who had a negative low-dose computed tomography (CT) prevalence screen had a low incidence of lung cancer detected at first annual screen and exhibited reduced...
ASCO Endorses Cancer Care Ontario Recommendations on Decision-Making in Adjuvant Systemic Therapy for Early-Stage, Operable Breast Cancer
As reported in the Journal of Clinical Oncology by N. Lynn Henry, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and colleagues, ASCO has endorsed Cancer Care Ontario (CCO) guideline recommendations on the role of patient and disease factors in decisions on adjuvant systemic...
Lower Vitamin D Levels Associated With Adverse Pathology at Prostatectomy in Men With Localized Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Nyame et al found that lower serum 25-hydroxyvitamin D (25-OH D) levels were associated with an increased likelihood of adverse pathology at radical prostatectomy in men with localized prostate cancer. Study Details The cross-sectional...
Increased Frequency of BRCA Mutation Testing in Young Women With Breast Cancer
Rosenberg et al found that the proportion of women diagnosed with breast cancer at age ≤ 40 years who have undergone BRCA1 and BRCA2 testing has increased during recent years. These findings, which were reported in JAMA Oncology, were part of the ongoing prospective Helping Ourselves, Helping...
